Mystic Pharmaceuticals has announced that the United States Patent and Trade Office issued a Notice of Allowance for the company’s patent application titled “Medical Devices For Dispensing Powders” (application #13/433,586). The technology is an extension of the company’s VRx2 delivery platform and can be used for nasal, buccal, sublingual and opthalmic powder delivery.
In 2013, the company announced that it had received a US patent titled “Intranasal Cartridge Devices”, several notices of allowance for US patents related to its VersiDoser and VRx2 delivery platforms and Chinese and Japanese patents for its delivery technology.
Mystic President and CEO Timothy Sullivan commented, “Drugs and biologics formulated, packaged and delivered as powders offer tremendous benefits for product stability and can eliminate the need for cold chain management. Our technology provides precision delivery of prescription medications utilizing low cost, mono-dose or multi-dose dispensers without the expense and complexity of volatile propellants.”
Read the Mystic press release.
